Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Surprise German Decision Boosts Jardiance Pricing Potential

Executive Summary

Boehringer Ingelheim/Lilly’s Jardiance has become one of the first of the newer antidiabetic agents to be viewed favorably by Germany's health technology assessment body, the G-BA. The surprise ruling paves the way for favorable pricing discussions.

You may also be interested in...

Keeping Track: Sandoz Erelzi Is Third Biosimilar To Clear FDA; Expanded Labels For Arzerra, Blincyto

The latest drug development news and highlights from our FDA Performance Tracker.

Cardiovascular Data To Propel Jardiance Ahead Of Rivals

The sodium-glucose cotransporter-2 (SGLT-2) inhibitor Jardiance (empagliflozin; Boehringer Ingelheim/ Eli Lilly) is expected to experience a significant increase in uptake in the type 2 diabetes market after the presentation of its much-anticipated cardiovascular (CV) outcomes data at the 51st European Association for the Study of Diabetes Annual Meeting in Stockholm, Sweden.

Sensing No Room For Price Compromise, Janssen Pulls Invokana From Germany

After a disappointing assessment from Germany’s two reimbursement bodies, Janssen has opted to withdraw it diabetes drug, believing it cannot secure a competitive price.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts